Real world data shows that Stelara offers lower rates of psoriasis infection

New interval findings from an international prospective disease-based registry provide a review of important patient outcomes related to systemic psoriasis treatments including Stelara (ustekinumab) from US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen.

The prospective, disease-based Psoriasis Longitudinal Assessment and Registry (PSOLAR) study was designed to assess therapeutic risk and benefits in a population of patients with moderate to severe psoriasis, while also meeting the needs for post-marketing surveillance of biologics including those marketed by Janssen. The data were presented at the 72nd Annual Meeting of the American Academy of Dermatology (AAD) in Denver, Colorado, USA.

Data collected over two years